Barclays’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12.2M | Sell |
339,362
-27,868
| -8% | -$1M | ﹤0.01% | 1042 |
|
|
2025
Q1 | $11.4M | Buy |
367,230
+3,922
| +1% | +$122K | ﹤0.01% | 944 |
|
|
2024
Q4 | $9.27M | Buy |
363,308
+54,421
| +18% | +$1.39M | ﹤0.01% | 1174 |
|
|
2024
Q3 | $8.74M | Buy |
308,887
+43,339
| +16% | +$1.23M | ﹤0.01% | 1117 |
|
|
2024
Q2 | $7M | Sell |
265,548
-19,341
| -7% | -$510K | ﹤0.01% | 1026 |
|
|
2024
Q1 | $8.65M | Sell |
284,889
-117,229
| -29% | -$3.56M | ﹤0.01% | 1104 |
|
|
2023
Q4 | $11.3M | Sell |
402,118
-911,961
| -69% | -$25.6M | ﹤0.01% | 994 |
|
|
2023
Q3 | $35.7M | Buy |
1,314,079
+210,414
| +19% | +$5.71M | 0.02% | 542 |
|
|
2023
Q2 | $33.9M | Buy |
1,103,665
+670,204
| +155% | +$20.6M | 0.02% | 550 |
|
|
2023
Q1 | $15.6M | Buy |
433,461
+31,271
| +8% | +$1.13M | 0.01% | 674 |
|
|
2022
Q4 | $15.9M | Buy |
402,190
+181,497
| +82% | +$7.17M | 0.01% | 707 |
|
|
2022
Q3 | $8.87M | Buy |
220,693
+9,914
| +5% | +$398K | 0.01% | 861 |
|
|
2022
Q2 | $8.86M | Buy |
210,779
+25,219
| +14% | +$1.06M | 0.01% | 864 |
|
|
2022
Q1 | $7.23M | Buy |
+185,560
| New | +$7.23M | 0.01% | 1000 |
|